Intestinal alkaline phosphatase (IAP, IAP Enhancer) attenuates intestinal inflammation and alleviates insulin resistance

Chenzhe Gao1,2, Marwa Yagoub Farag Koko2, Mingxing Ding3, Weichen Hong1, Jianping Li2, Na Dong1*† and Mizhou Hui2*†

1The Laboratory of Molecular Nutrition and Immunity, Institute of Animal Nutrition, Northeast Agricultural University, Harbin, China, 2College of Food, Northeast Agricultural University, Harbin, China, 3Changchun Jiahe Surgery Hospital, Changchun, China

In this study, we investigated the effects of intestinal alkaline phosphatase (IAP) in controlled intestinal inflammation and alleviated associated insulin resistance (IR). We also explored the possible underlying molecular mechanisms, showed the preventive effect of IAP on IR in vivo, and verified the dephosphorylation of IAP for the inhibition of intestinal inflammation in vitro. Furthermore, we examined the preventive role of IAP in IR induced by a high-fat diet in mice. We found that an IAP + IAP enhancer significantly ameliorated blood glucose, insulin, low-density lipoprotein, gut barrier function, inflammatory markers, and lipopolysaccharide (LPS) in serum. IAP could dephosphorylate LPS and nucleoside triphosphate in a pH-dependent manner in vitro. Firstly, LPS is inactivated by IAP and IAP reduces LPS-induced inflammation. Secondly, adenosine, a dephosphorylated product of adenosine triphosphate, elicited anti-inflammatory effects by binding to the A2A receptor, which inhibits NF-κB, TNF, and PI3K-Akt signalling pathways. Hence, IAP can be used as a natural anti-inflammatory agent to reduce intestinal inflammation-induced IR.

KEYWORDS
intestinal inflammation, intestinal alkaline phosphatase, lipopolysaccharide, adenosine, dephosphorylation, signalling pathway

Introduction

Type 2 diabetes (T2DM) is a major global health problem, and its incidence increases every year. In 2019, the latest epidemiological data showed that the number of adults with T2DM reached 463 million (1). A hallmark of T2DM is insulin resistance (IR), which is associated with metabolic disorders (2). Despite the rapid development of global technology, no complete consensus on the pathogenesis of IR has been presented, illustrating the complexity and refractory nature of IR.
Intestinal inflammation is one of the most important causes of IR (3). In mammals, the gut is the largest immune organ that contains secondary immune organs, the structure of the tertiary lymphoid, and immune cells scattered throughout the lamina propria and intraepithelial spaces of the intestine, which work together to protect the body from foreign substances (4). Moreover, inflammatory mediators such as IL-13, TNF-α, and IFN-γ damage the integrity of the epithelial barrier and increase the degree of intestinal inflammation (5). Therefore, strategies that can reduce intestinal inflammation must be developed.

LPS acts as a toxin by overstimulating the innate immune signalling of Toll-like receptor 4 (TLR4), which induces an exacerbated inflammatory response (6). Nevertheless, IAP can detoxify bacterial LPS via dephosphorylation (7). Lipid A is responsible for LPS toxicity and composed of two phosphate groups coupled to glucosamines, allowing LPS to bind to TLR4, triggering an inflammatory response (7). However, the removal of one of the phosphate groups from lipid A by IAP produces a monophosphoryl lipid A, which is 100 times less toxic than unmodified lipid A (8).

In the initiation of inflammation, extracellular purines (adenosine, ADP, and ATP) and pyrimidines (UDP and UTP), which are released from host cells including nerve termini, immune cells, injured or dead cells, and the commensal bacteria that reside in the gut lumen, stimulate purinergic receptors in autocrine and paracrine ways (9). Once released, extracellular ATP (eATP) is rapidly hydrolysed to ADP, AMP, adenosine by IAP (10). The latter exerts intestinal protective and anti-inflammatory effects by binding to one of the four adenosine receptors A1, A2A, A2B, and A3 (11). M. Estaki et al. (6) reported that metabolic syndrome develops in IAP knockout mice fed with high fat, but this condition can be alleviated by oral IAP. In addition, IAP overexpression attenuates the attenuated development of WD-induced atherosclerosis by limiting the translocation of gut-derived LPS or reducing plasma lipids (12). Therefore, oral IAP supplementation represents a novel therapy to counteract the chronic inflammatory state leading to frailty and age-related diseases in humans (13).

IAP is a phosphomonoesterase that catalyses the hydrolysis of non-specific phosphate ester bonds, whose activity is positively correlated with pH (14). We aimed to build on these findings by determining whether pharmacologic approaches that trigger IAP activity by increasing pH in the gut could reduce intestinal inflammation and elicit a palliative effect on IR. Earlier laboratory studies suggested the use of oral hydrotalcite as an IAP enhancer, which can improve IAP activity by regulating intestinal pH to alkalisation in the treatment of LPS-associated intestinal inflammatory diseases (15).

However, studies have yet to explore how IAP deficiency is linked to these diseases. Therefore, this study was designed to investigate the protective role of IAP during intestinal inflammation and reveal the underlying molecular mechanisms of action that would delay the further development of inflammatory bowel disease and IR. This study also aimed to explore the safety and initial efficacy of IAP and provide a basis for using IAP as a potential biological treatment for IR caused by intestinal inflammation.

### Materials and methods

#### Simulation of gastrointestinal digestive properties by an IAP enhancer in vitro

Simulated gastric juice was prepared by supplementing 2 g NaCl, 1.12 g KCl, 0.11 g CaCl, and 0.4 g KH₂PO₄, and its volume was fixed to 1,000 ml in distilled water. Then, the juice was sterilised (121°C, 15 min) and added to 3 g/l pepsin (Sigma, USA). Buffer solution broth was prepared by adjusting the pH to 2.5 with 1 mol/l HCl. Simulated intestinal juice was prepared by supplementing 10 g/l trypsin (Sigma, USA) and 3.0 g/l bile salt (Sigma, USA) added into an artificial gastric fluid, and pH was adjusted to 6.5 with 1 mol/l NaHCO₃.

Hydrotalcite, oat flour, and IAP enhancer (composed of oatmeal, shell powder, aluminium hydroxide, calcium carbonate, magnesium carbonate, xylitol, etc.) were used as raw materials (through the puffing extrusion method, Qingdao Dr. Hui Biological Technology Co., Ltd., China, SCI122370684001877; Table S1) by 10% (W/V) access to artificial gastric juice and digested in a shaker at 100 r/min and 37°C for 1 h. The artificial intestinal juice was added at 10% (W/V) and digested in a shaker at 100 r/min and 37°C for 6.5 h, i.e., simulated duodenal digestion for 0.5 h and intestinal digestion and absorption for 6 h (16).

#### IAP and LPS activity

Tris–HCl buffer (50 mmol/l) was adjusted to pH 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, and 8.0 by using HCl (1 mol/l). Then, 0.1 ml IAP (IAP [molecular weight of 59 kDa and purity of 95.71%] purified from fresh pig intestinal mucosa via ion chromatography; College of Food, Northeast Agricultural University, China) was added to 0.9 ml buffer solution with different pH levels. The IAP activity was measured using an alkaline phosphatase detection kit (TE0005, Nanjing Jiancheng Biotechnology Co., Ltd., China) (17).

IAP (0.5 mL, 400 U/ml) was added to Tris–HCl buffer (4.5 mL, 50 mmol/l), and the final pH was adjusted to 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, and 8.0. LPS (E. coli 0111: B4, Sigma, USA) was diluted to 0.1 mg/ml with Tris–HCl buffer (50 mmol/l, pH = 8.0). Then, 10 µl of the diluted LPS solution (pH = 8.0) was added to 990 µl of IAP solutions at pH 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, and 8.0. and incubated at 37°C for 80 min. IAP was diluted to 1, 5, 10, 20, and 40 U/ml by using Tris–HCl buffer (50 mmol/l, pH = 8.0). Afterwards, 10 µl...
of LPS (0.1 mg/ml) was added to 990 µl of IAP solution with different IAP activities to obtain an LPS concentration of 1 µg/ml. The mixtures were incubated at 37°C for 180 min. LPS activity was determined using a quantitative Limulus endotoxin detection kit (EC32545S, Xiamen Biotechnology Co., Ltd., China) via the chromogenic matrix method (18).

Free phosphate

In this procedure, 950 µl of IAP at 40.00 U/ml (pH 8.0) and 0.40 U/ml (pH 8.0) at different pH levels was used in this experiment. Then, 50 µl of a solution containing ATP, adenosine diphosphate (ADP), adenosine monophosphate (AMP), uridine triphosphate (UTP), uridine diphosphate (UDP), uridine monophosphate (UMP), guanosine triphosphate (GTP), guanosine diphosphate (GDP), guanosine monophosphate (GMP), cytidine triphosphate (CTP), cytidine diphosphate (CDP), cytidine monophosphate (CMP), thymidine triphosphate (TTP), thymidine diphosphate (TDP), thymidine monophosphate (TMP) (10 mmol/l, YuanYe Biotechnology Co., Ltd., China) with the same pH was added. The mixture was incubated at 37°C for 60 min. Afterwards, 10 µmol/l TDP, thymidine monophosphate (TDP), thymidine diphosphate (TDP), thymidine monophosphate (TMP) (10 mmol/l, YuanYe Biotechnology Co., Ltd., China) with the same pH was added. The mixture was incubated at 37°C for 60 min. Free phosphate was assessed using a free phosphate detection kit (EC32545S, Xiamen Biotechnology Co., Ltd., China). Fasting and postprandial insulin levels were determined using an alkaline phosphatase detection kit (Mindray, China). Fasting and postprandial blood glucose, triglyceride, cholesterol, low-density lipoprotein, and high-density lipoprotein for mice). Fasting and postprandial blood glucose, triglyceride, cholesterol, low-density lipoprotein, and high-density lipoprotein were measured using a BS-280 automatic biochemical analyser (Mindray, China). Fasting and postprandial insulin levels were determined via radioimmunoassay by using UniCel Dx1800 automatic chemiluminescence immunoassay (Beckman, USA).

Animal experiment

Twelve-week-old male C57BL/6J mice (Long-Life Biotechnology, Liaoning, China) were maintained in filter-top cages in a temperature-controlled room (22°C–24°C) with a 12-h light/12-h dark diurnal cycle and given food and water ad libitum in accordance with the regulations designated and approved by the Northeast Agricultural University Committee on Animal Resources (UCAR), which adheres to FDA and NIH animal care guidelines and reviews all animal protocols prior to approval (NEAUEC20220231).

The mice were placed on a high-fat diet (HFD: D12451; 35 E% from carbohydrate, 20 E% from protein, and 45 E% from fat, Research Diets). After 14 weeks of HFD treatment, those that exhibited obesity and IR, as measured by fasting blood glucose ≥11.1 mmol/l, were used in the study (n = 32). HFD-fed mice were randomly divided into four groups. 1) In the control group, mice (n = 8) were administered with a control vehicle; 2) in the IAP group, mice (n = 8) were given 100 U/100 g/day IAP; 3) in the IAP enhancer group, mice (n = 8) were provided with 5 g/1,000 g/day IAP enhancer; and 4) in the IAP + IAP enhancer group, mice (n = 8) were treated with 100 U/100 g/day IAP + 5 g/1,000 g/day IAP enhancer. The treatments were administered by gavage at 9 a.m. for 4 weeks (19–21). As a low-fat diet (LFD) control group (n = 8), the mice were placed on LFD (D12450HL; 70 E% from carbohydrate, 20 E% from protein, and 10 E% from fat, Research Diets).

Basic indicators

Body weight was measured using a scale (LE/KA, China). Faecal samples were collected at baseline and 4 weeks after treatments. Urine was collected via bladder massage at 3 p.m. (6 h after the experiment started) and after 24 h to measure pH. Urine samples were collected by gentle abdominal pressure and analysed with a BW-901 urine analyser (Mindray, China). Blood samples were drawn from the tip of the incised tail after the mice fasted for 8 h, and analysis was completed within 24 h. GTT was performed after overnight (8:00 p.m.–8:00 a.m.) fasting. The glucose levels of the tail vein blood samples were measured 0, 15, 30, 60, and 120 min after oral administration of glucose (2 g/1,000 g for mice). Fasting and postprandial blood glucose, triglyceride, cholesterol, low-density lipoprotein, and high-density lipoprotein were measured using a BS-280 automatic biochemical analyser (Mindray, China). Fasting and postprandial insulin levels were determined via radioimmunoassay by using UniCel Dx1800 automatic chemiluminescence immunoassay (Beckman, USA).

Faecal IAP activity

In this procedure, 0.1 g of fresh faecal sample was taken from the mice; each sample was added with 5 ml of Tris–HCl buffer (50 mmol/l, pH = 8.0), mixed, and centrifuged at 12,000 r/min and 4°C for 10 min. The supernatant was diluted to 100-fold, and faecal IAP levels were determined using an alkaline phosphatase detection kit (TB0005, Nanjing Jiancheng Biotechnology Co., Ltd., China). The result was reported as units per gram (22).

Plasma LPS, CRP, GLP-1, TNF-α, IL-6, IL-17, IFN-γ, and IL-22

Plasma was collected from the LFD control group. Then, the plasma was added to a processing solution (Xiamen Limulus Reagent Biotechnology Co., Ltd., China) at a ratio of 1:9, and the mixture was incubated in a water bath at 70°C for 10 min and cooled for 3 min. LPS at final concentrations of 0.00, 2.50, 6.25, and 12.50 pg/ml was used to generate a standard curve for plasma LPS measurements. The plasma samples to be tested were added to the same processing solution at a ratio of 1:9, and the mixture was incubated in a water bath at 70°C for 10 min and then cooled for 3 min. Plasma LPS was measured using a Limulus endotoxin detection kit (EC32545S, Xiamen
Biotechnology Co., Ltd., China). Every obtained result was multiplied by 10-fold because of sample dilution (20).

The collected plasma and the levels of CRP, GLP-1, TNF-α, IL-6, IL-17, IFNγ, and IL-22 were measured using ELISA kits (Mlbio, China).

**Intestinal permeability assay**

Six-centimetre segments of the intestine were removed, rinsed with ice-cold saline, everted, filled with 700 ml of PBS, and ligated at both ends. The filled jejunum segments were incubated in PBS containing 1 mol/l FITC-dextran (70 kDa; Sigma) or 0.4 mg/ml HRP (type IV, 300 units/mg solid, Sigma-Aldrich Co.). The jejunum sacs were removed after 45 min, and the contents of each sac were collected carefully using a 1-ml syringe. The amount of FITC-dextran transversing the jejunum was quantified by using a fluorescence plate reader at 521 nm. The HRP activity in the contents of each sac was determined spectrophotometrically based on the rate of pyrogallol oxidation (23).

Evans blue penetration assay: Briefly, Evans blue dye (4% in saline) was administered at 4 ml/kg via the tail vein for 2 h. After being anesthetized with 1% pentobarbital, the mice were perfused with normal saline to wash residual dye out of the blood vessels. Intestinal samples were then collected to evaluate intestinal barrier disruption. Evans blue was extracted from tissue homogenates incubated in formamide at 60°C for 24 h. Then, the infiltrated Evans blue was quantified using a spectrophotometer at 620 nm. The content of the dye was calculated with a standard curve method (24).

**Histological staining**

The collected jejunum tissues were fixed with 4% paraformaldehyde and embedded in paraffin. Paraffin-embedded jejunum tissues were sectioned (4 µm in thickness), quickly stained with haematoxylin and eosin (HE), mounted on slides, and examined using a US Moticam 3000 photomicrography imaging system for observations and photography.

**Cell culture**

All the cell lines passed the mycoplasma contamination detection. HT-29 cells (Hubei Yuze Pharmaceutical Technology Co., Ltd., China), which were used as an in vitro model to study absorption, transport, and secretion by intestinal cells, were inoculated in McCoy’s 5A medium (HyClone, USA) containing 10% FBS. They were added onto the top of a confluent HT-29 cell monolayer at a density of 1.0 × 10^5 cells/well. Physical examinations, electrocardiography, and routine laboratory studies on all healthy participants before the start of the experiment showed normal results. The healthy participants were not taking any prescription medications and tested negative for hepatitis B surface antigen and human immunodeficiency virus infection. This study was reviewed and approved by the Institutional Changchun Jiahe Surgical Hospital (Changchun, Jilin Province; Ethical Approval No. 2019712) and complied with the Declaration of Helsinki including current revisions and the Good Clinical Practice guidelines. Written informed consent was obtained from all study participants.

An LPS-induced intestinal inflammation model of HT-29 cells + freshly extracted human leucocytes was established by adding 100 µl of LPS to each well, and the final concentrations were 0.10, 0.20, 1.00, and 2.00 ng/ml. Then, 100 µl of IAP (40 U/ml; 100 µl of LPS (1.0 ng/ml), 50 µl of IAP (4, 20, 40, 80 U/ml) + 50 µl of LPS (2.0 ng/ml), 50 µl of IAP (80 U/ml), and 50 µl of LPS (2.0 ng/ml) were incubated for 3 h in advance or at the same time; IAP (80 U/ml) was inactivated in a water bath at 65°C for 60 min, as well as the following: 50 µl of inactive IAP and 50 µl of LPS (2.0 ng/ml); 50 µl of IAP (40 U/ml) + 50 µl of ATP/UTP/GTP/CTP/TPP (4.0 mmol/l); 50 µl of IAP (2/10/20/40 U/ml), and 50 µl of ATP (4.0 mmol/l); 100 µl of ATP, ADP, AMP, and adenosine (YuanYe Biotechnology Co., Ltd., China) at final concentrations of 0.10, 0.25, 0.50, and 1.00 mmol/l; 50 µl of IAP (40 U/ml) and 50 µl of IAP (40 U/ml) + 50 µl of CCPA, DPCPX, CGS21680, DMPX, NECA, MRS1754, CI-IB-MECA, and MRS1220 (4–40,000 nmol/l, Sigma, USA); and 100 µl of uridine, guanosine, cytidine, and thymidine (YuanYe Biotechnology Co., Ltd., China). Additionally, 100 µl of adenosine (2.0 mmol/l) and 50 µl of adenosine (2.0 mmol/l) + 50 µl of uridine, guanosine, cytidine, and thymidine (2.0 mmol/l) were added at final concentrations of 0.10, 0.25, 0.50, and 1.00 mmol/l. All groups were added to the same cell line and cultured at 37°C for 24 h.

**Determination of pro-inflammatory cytokines**

Supernatants were collected, and TNF-α and IL-6 levels were determined using ELISA (R&D Systems, UK). The supernatant was collected after LPS administration, with or without IAP, adenosine, adenosine + uridine, guanosine, cytidine, and thymidine pretreatment. Then, 50 µl of the
supernatant in each well was absorbed into blank plate wells. Afterwards, 50 µl of Griess A (5% H3PO4 solution containing 1% sulfa) and Griess B (1% N-1-naphthyl-ethylenediamine-hydrochloric acid solution) were added, and the OD value of each well was measured at 570 nm. PGE2 was determined using a prostaglandin E2 assay kit (H099-1, Nanjing Jiancheng Biotechnology Co., Ltd., China) (25).

**Cell viability**

The control group was treated with 100 µl of RPMI-1640 complete medium, and the experimental group was treated with 100 µl of LPS (1.0 ng/ml), 100 µl of IAP (40 U/ml), and 50 µl IAP (4/20/40/80 U/ml) + 50 µl LPS (2.0 ng/ml). Additionally, 100 µl of adenosine (2.0 mmol/l) and 50 µl adenosine (2.0 mmol/l) + uridine, guanosine, cytidine, and thymidine (2.0 mmol/l) were added to the cell lines and cultured at 37°C for 24 h. The supernatant was discarded, and adherent cells were observed under an inverted phase-contrast microscope (OLYMPUS, Japan) at 0, 24, and 36 h.

**Wound healing assay**

Control, LPS, IAP, IAP + LPS, adenosine, and adenosine + uridine, guanosine, cytidine, and thymidine were seeded in a six-well plate. Scratches were generated using a 1-ml micropipette tip when the cells reached 100% confluence. The cells were then washed twice with PBS and incubated in a complete medium at 37°C. Images were observed under an inverted phase-contrast microscope (OLYMPUS, Japan) after 0, 48, and 72 h. Cell areas were quantified using ImageJ, and cell migration was defined as [Cell area (48/72 h)−Cell area (0 h)/Cell area (0 h)] (27).

**ATP, ADP, AMP, and adenosine release**

The supernatant was collected 20 min after LPS administration, with or without IAP pretreatment. ATP, ADP, AMP, and adenosine production were directly measured using the Bioluminescence Assay Kit CLS II (Mibio, China).

**RNA sequencing and data analysis**

HT-29 cells were inoculated on six-well plates (4.0 × 10⁴ cells/well) in the presence of 5% CO₂ at 37°C for 24 h. The supernatant was removed, and 1 ml of freshly extracted leucocytes (2 × 10⁵ cells/well) was added. The control group was supplemented with 1 ml of RPMI-1640 medium, and the LPS group was added with 1 ml of LPS (1.0 ng/ml). The IAP + LPS group was added with 500 µl of IAP (40 U/ml) and 500 µl of LPS (0.5 ng/ml). The adenosine group was added with 1 ml of adenosine (2 mmol/l). Plates were then centrifuged, and supernatants were discarded. Total RNA was extracted from the mycelia by using TRizol reagent (Sigma, USA). The quantity and purity of the RNA were assessed via 1% agarose gel electrophoresis and NanoDrop 2000 (Thermo Fisher Scientific, MA, USA). RNA was quantified using a Qubit3.0, Agilent 2100, StepOnePlus™ Real-Time PCR System (Thermo Fisher Scientific, MA, USA). RNA integrity was examined with an RNA Nano 6000 assay kit of the Bioanalyser 2100 system (Agilent Technologies, CA, USA).

**Quantitative real-time PCR**

Total RNA was extracted from the mouse jejunum tissue and cell lines by using the TRIzol reagent. cDNA was diluted to 2 ng/µl for quantitative PCR. The primers were designed using Primer3.0. Then, 2× SYBR® Green premix was used in the reaction system. Table S2 shows the real-time fluorescence quantitative PCR system, and Table S3 presents the real-time fluorescence quantitative PCR. The program was set as follows: 95°C, 5 min → 95°C, 15 s → 60°C × 30 s; the whole process was 40 cycles. The relative expression levels of differential genes were analysed with 2^ΔΔCt.

**Statistical analysis**

Data were statistically analysed using SPSS, expressed as mean ± SD, and examined using two-tailed unpaired Student’s t test. Statistically significant differences between more than two test groups were evaluated via one-way analysis of variance with Tukey’s multiple-comparison posttests. Differences were considered significant when P < 0.05.

**Results**

**Dephosphorylation properties of IAP**

We first examined the dephosphorylation of IAP on LPS or nucleoside triphosphate in vitro to reduce the intestinal inflammatory response and prevent IR caused by intestinal
inflammation. We simulated the slow-release effects of the IAP enhancer in a simulated gastrointestinal environment. When the IAP enhancer and hydrotalcite mixture interacted with the artificial stomach acid, both exhibited a good slow-release ability and could not be resolved by the acid. Consequently, it could reach the duodenum and small intestine and exhibit a good slow-release ability to increase the pH of the small intestine in vitro (Figure 1A). Thus, the IAP activity improved. We further demonstrated that increasing pH was an effective way to enhance IAP activity in vitro (Figure 1B).

LPS induces inflammatory factors that interfere with insulin signalling and contribute to IR (28). It releases inorganic phosphate through the IAP dephosphorylation (12). LPS was dephosphorylated by IAP in a pH-dependent manner (Figure 1C) and dose-dependent manner (Figure 1D) in vitro. The results were further investigated to determine whether IAP could dephosphorylate nucleoside triphosphate in vitro. IAP could further dephosphorylate ATP (Figure 1E) and its products ADP (Figure 1F) and AMP (Figure 1G) in a pH-dependent manner; however, when the activity was high enough, pH slightly affected dephosphorylation (Figure S1). IAP dephosphorylation was compared with the hydrolyase CD39 and CD73 of ATP, ADP, and AMP. As expected, the effect of IAP was similar to that of CD39 and CD73, which dephosphorylated ATP (Figure 1H), ADP (Figure 1I), and AMP (Figure 1J) to adenosine. Furthermore, IAP dephosphorylation was dependent on pH for other nucleoside triphosphates such as UTP, UDP, and UMP (Figure S2); GTP, GDP, and GMP (Figure S3); CTP,
CDP, and CMP (Figure S4); and TTP, TDP, and TMP (Figure S5). Therefore, pH had an undecisive role in these ligands during a high IAP activity (Figures S6–S9).

**Intervention effect of IAP and IAP enhancer in mouse models**

We next investigated whether IAP and IAP enhancer could reverse any features of IR. We observed a higher body weight in the HFD group than in the other groups; however, IAP and IAP enhancer prevented the HFD-induced increase in body weight especially in the IAP + IAP enhancer group (Figure S10). Compared with the vehicle, the oral glucose tolerance of the mice treated with IAP + IAP enhancer was better (Figure 2A and Figure S11) than that of the mice administered with either IAP or IAP enhancer. The lowest fasting and postprandial insulin was observed in the IAP + IAP enhancer group (Figure 2B). Cholesterol, triglyceride, and high-density lipoprotein did not significantly vary among the three groups (Figures S12A–C). Low-density lipoprotein levels were the most significant in the IAP + IAP enhancer group (Figure 2C). Based on the IAP activity influenced by pH, the IAP activity was increased by increasing the intestinal pH in vivo. Urine pH was improved in the IAP enhancer and IAP + IAP enhancer groups, reaching the urine pH of the LFD control group (Figure S12D). This result was consistent with our hypothesis that urine pH was positively correlated with intestinal pH. As such, we measured the IAP activity in the faecal sample. The HFD-fed mice had less faecal IAP activity than the LFD control group, but the faecal IAP activity of the HFD-fed mice increased significantly after the treatment, especially in the IAP + IAP enhancer group (Figure 2D). Plasma LPS levels were much higher in the HFD-fed mice than in the LFD control group, but these levels were reduced after the treatment (Figure 2E). These results supported the concept that IAP prevented LPS activity by detoxifying LPS within the intestinal lumen (12). The plasma CRP level significantly decreased in the three groups; among them, the IAP + IAP enhancer group had the best effect on reducing the inflammation level. However, none of the three groups could reach the level of the LFD control group after intervention (Figure 2F). IAP, IAP enhancer, and IAP + IAP enhancer significantly increased the plasma GLP-1 levels, and their effects exhibited the following trend: IAP < IAP enhancer < IAP + IAP enhancer (Figure 2G). The three intervention groups could promote GLP-1 secretion by intestinal mucosa L cells and reduce blood glucose, which affects IR (29). To further assess the local inflammatory status within the intestine, we measured plasma TNF-α and IL-6 levels and found that the levels of HFD mice were significantly higher than those of the LFD control group (Figures 2H, I); those treated with IAP + IAP enhancer showed the lowest levels.

IL-17, IFNγ, and IL-22 alter tight junction activity (30). As depicted, serum IL-17 and IFNγ concentrations significantly increased, whereas IL-22 concentrations decreased in the HFD mice. Compared with those in the IAP and IAP enhancer, IAP + IAP enhancer treatment significantly reduced the concentrations of IL-17 and IFNγ (Figures 3A, B) but increased the concentration of IL-22 (Figure 3C). These results indicated that IAP + IAP enhancer could restore intestinal barrier function by controlling relevant cytokines in vivo.

Intrigued by these results, we examined the effect of IAP + IAP enhancer on the jejunal epithelium of HFD-fed mice with disrupted intestinal barrier functions. HFD mice orally administered with IAP + IAP enhancer had normal expression patterns and mRNA levels of claudin-1 (Figure 3D), occludin (Figure 3E), and ZO-1 (Figure 3F), which are tight junction-associated proteins that play pivotal roles in gut homeostasis (31). Furthermore, in comparison with other treatments, IAP + IAP enhancer remarkably prevented the systemic exposure of FITC-dextran after oral administration in the HFD model group (Figure 3G), demonstrating the restoration of intestinal barrier functions. The HRP flux more significantly decreased in the IAP + IAP enhancer group than in the other groups (Figure 3H). When the intestinal contents were tested with Evans blue, the colour was lighter in the IAP + IAP enhancer than in the other treatments (Figure 3I).

Histological observation showed no damage on the jejunum of the control + LFD group (Figure 4A), but the jejunal structure of the control + HFD group was damaged, and the villi were broken and scattered (Figure 4B). However, the jejunal structure of the IAP + IAP enhancer group was significantly improved compared with that of the control + HFD group, and the villi were arranged neatly (Figure 4C).

**Anti-inflammatory mechanism of IAP in vitro**

HT-29 cells + freshly extracted human leucocytes were used to establish a model of TNF-α and IL-6 produced by LPS stimulation. The LPS concentration was 0.5 ng/ml, and the TNF-α (Figure S13A) and IL-6 (Figure S13B) contents continuously increased until the maximum values were reached. Moreover, with the participation of leucocytes, more TNF-α/IL-6 could be produced in the coculture system even without treatment. IAP could inhibit TNF-α and IL-6 in the model with or without LPS. The results suggested that IAP could reduce inflammation via another anti-inflammatory pathway other than LPS inactivation in vitro. When the LPS concentration was 0.5 ng/ml, the reduction of TNF-α (Figure 5A) and IL-6 (Figure 5B) showed a dose-dependent relationship with IAP activity. A similar protective result was obtained when the IAP was incubated with LPS for 3 h in
advance or simultaneously (Figures 5C, D). The effect of inactive IAP lacking its hydrolysing properties was investigated to confirm that the IAP-induced reduction in cytokine production was due to the dephosphorylating nature of the enzyme. Inactive IAP did not attenuate the LPS-induced inflammatory response in the model (Figures 5E, F). Additionally, IAP inhibited the inflammatory markers NO (Figure 5G) and PGE₂ (Figure 5H) in a dose-dependent manner to further assess the inflammatory status within the intestine.

The proliferation, differentiation, and survival of intestinal epithelial cells are regulated by cytokines, such as TNF-α and IL-6 (32). Therefore, the inflammation degree was affected by HT-29 cell proliferation. IAP could significantly inhibit cell proliferation, while LPS could significantly promote cell proliferation. When IAP was co-incubated with LPS, inhibition was positively correlated with IAP dose (Figure S14).

After 24 h, the control group and the experimental group did not have noticeable morphological changes. After 36 h, the control group cells showed an irregular shape, large volume,
and small intercellular space. The cell volume gradually decreased, and the cells became round; the cell wall was not firm. After LPS treatment, cell proliferation was induced, resulting in tighter intercellular connections. When treated with IAP + LPS, the number of cells decreased, and the shape of cells gradually enlarged. The dead cells and debris were suspended (Figure 6).

Cytomorphogenesis and inflammation were evaluated in terms of cell migration (33). IAP significantly inhibited the migration of HT-29 cells at 48 and 72 h compared with that of the control group. After LPS treatment, HT-29 cell migration was significantly stimulated. Cell migration was significantly reduced after co-incubation with LPS and IAP at 48 and 72 h (Figure 7).

Based on the known IAP activity and our data on luminal LPS, our results suggested that IAP may prevent IR through another mechanism that involves the luminal dephosphorylation of ATP and other substances associated
with inflammation except LPS dephosphorylation (34). We tested five IAP targets, namely, ATP, UTP, GTP, CTP, and TTP, and discovered that UTP, GTP, CTP, and TTP had no significant tendency on cytokines after dephosphorylation by IAP. However, ATP significantly changed the TNF-α (Figure 8A) and IL-6 (Figure 8B) levels. Furthermore, the TNF-α and IL-6 levels increased significantly after GTP and TTP dephosphorylation by IAP (Figures 8A, B).

The results showed the anti-inflammatory effect of the different activities of IAP on ATP dephosphorylation and found that TNF-α (Figure 8C) and IL-6 (Figure 8D) were inhibited by ATP dephosphorylation in a dose-dependent manner in vitro. On this basis, we examined the anti-inflammatory effects of ATP and its dephosphorylated products ADP, AMP, and adenosine. ATP (Figures S15A, B) has no anti-inflammatory function. However, ADP (Figure...
S15C, D) and AMP (Figures S15E, F) had a significant anti-inflammatory effect; the inhibitory effect of adenosine (Figures S15G, H) was the most significant.

Extracellular ATP can be converted by ectonucleotidases into AMP and eventually into adenosine. Interestingly, this study showed that extracellular ATP and ADP concentrations increased after LPS incubation, but this increase was reversed by IAP pre-incubation. These concentrations respectively increased by 251.85% and 117.28% relative to the control after LPS stimulation; after the co-administration of IAP, these concentrations increased by 108.94% and 117.28%, respectively. Subsequently, IAP directly converted ATP and ADP into AMP and adenosine (Figures 8E–H). Therefore, adenosine was produced through the IAP dephosphorylation of ATP, ADP, and AMP. A2A and A2B could be the receptors of action (Figures 9A, B). As shown in Figures 9C, D, adenosine inhibited TNF-α and IL-6 through the A2A receptor in this model.

Although uridine and cytidine had anti-inflammatory effects, they were unstable and mainly restricted by dose...
condition; guanosine and thymidine had no anti-inflammatory function (Figure S16). However, adenosine combined with cytidine and thymidine had significant synergistic effects (Figures 9E, F). Compared with the control group, adenosine combined with other nucleosides had extremely significant inhibitory effects on TNF-α (Figures 9E) and IL-6 (Figure 9F).
Moreover, adenosine inhibited the concentrations of NO (Figure 9G), PGE2 (Figure 9H), and proliferating cells (Figure S17) in a dose-dependent manner.

As shown in Figure 10, cell morphology did not significantly differ after 24 h. However, after 36 h, the cells in the adenosine and adenosine combined with other nucleoside groups showed increased roundness, significantly decreased adhesion ability, and had a better dispersion state compared with those in the control group. Conversely, the control group showed giant tumour cells and more fibroblast-like cells, scattered or connected by the cytoplasm. The cells adhered firmly to the wall and grew well.

For cell migration, adenosine combined with guanosine, cytidine, and thymine had a synergistic inhibitory effect compared with that of the adenosine group at 48 h. At 72 h, adenosine combined with cytidine only elicited a synergistic inhibitory effect (Figure 11).

**Transcriptome analysis of the anti-inflammatory effect of IAP in vitro**

To better understand the anti-inflammatory mechanisms of IAP to prevent IR by suppressing inflammation in vitro, we conducted a comparative transcriptomic analysis of the control, LPS, IAP + LPS, and adenosine groups. We found that 77 DEGs were upregulated and 193 DEGs were downregulated among the 270 DEGs in IAP + LPS vs. LPS (Figure S18A). Furthermore, 93 DEGs were upregulated and 244 DEGs were downregulated among the 337 DEGs in IAP + LPS vs. control (Figure S18B). In addition, 489 and 743 DEGs were upregulated or downregulated among the 1,232 DEGs in adenosine vs. control (Figure S18C).

The DEGs between the sample groups were then visualised using hierarchical clustering diagrams (Figure S19).

GO enrichment analysis indicated the biological process significantly associated with DEGs among IAP + LPS vs. LPS (Figure S20A), IAP + LPS vs. control (Figure S20B), and adenosine vs. control (Figure S20C).

KEGG database analysis revealed differences in 81 pathways (P < 0.05) in the IAP + LPS vs. LPS. Of the total differential KEGG pathways between IAP + LPS and LPS groups, 17 signalling pathways that were closely related to the immune system and signal transduction were selected (P < 0.05), and eight of these pathways were associated with intestinal inflammation, TNF, chemokine, Toll-like receptor, PI3K-Akt, JAK-STAT, IL-17, NOD-like receptor, and NF-kB signalling pathways (Figure 12A). The corresponding genes are shown in Figure 12B. CCL2 (35) and CX3CL1 (36) are essential cytokines in the TNF signalling pathway. CXCL9 (37) and CX3CL1 (38) can inhibit the chemokine signalling pathway. The expression levels of IL1B (39), IL-6 (40), and IFNB1 (41) significantly increased in IAP + LPS vs. LPS, which has a vital role in the Toll-like receptor signalling pathway. In the PI3K-Akt signalling pathway, the expression levels of IL1B (39), IL-6 (40), and IFNL1, IFNL2, and IFNL3 (43) were significantly lower in the IAP + LPS group than in the LPS group. The IL-17 signalling pathway involves some important regulatory molecules, such as CSF3 (44) and CCL2 (45), which were significantly different between the IAP + LPS and LPS groups. In the NOD-like receptor signalling pathway, the expression levels of HCK (46) were significantly lower in the IAP + LPS group than in the LPS group. The NF-κB signalling pathway involved the expression levels of HCK (46) were significantly lower in the IAP + LPS group than in the LPS group. The NF-κB signalling...
pathway showed a downward trend in the IAP + LPS group, and the expression levels of MEFV (47) and S100A8 (48) significantly decreased. The associated pathways in IAP + LPS vs. control were similar to those in IAP + LPS vs. LPS (Figure S21).

In comparison with the control group, 72 signalling pathways were identified after adenosine treatment (P < 0.05). Furthermore, 13 immune systems were screened in signal transduction pathways (P < 0.05) of which seven were closely related to intestinal inflammation: TNF, chemokine, NOD-like receptor, PI3K-Akt, Jak-STAT, IL-17, and MAPK signalling pathways (Figure 12C). As shown in Figure 12D, the same gene of the IAP + LPS group relevant for the TNF signalling pathway was downregulated in the adenosine group, indicating that the TNF signalling pathway is a potential inflammatory pathway in the adenosine group compared with that in the control group. CXCL13 (37), CXCR3 (37), CX3CL1 (49), and CCR3 (50), which participate in the chemokine signalling pathway were significantly downregulated after adenosine treatment. In the PI3K-Akt signalling pathway, LPAR1 (51), SHC3 (52), and EGF (53) were downregulated in the adenosine group. IFNL1, IFNL 2, IFNL 3 (43), and THPO (54) were downregulated, suggesting that the Jak-STAT signalling pathway was affected by adenosine. CSF3 (44), CCL2 (45), and TRAF6 (55) were also significantly inhibited, implying that the IL-17 signalling pathway was also involved in the suppression of intestinal inflammation by adenosine. Meanwhile, the HCK gene expression of the NOD-like receptor signalling pathway decreased in the adenosine group (46). Several genes, including THPO (54), PLA2G4C (56), and FASLG (57), relevant to the MAPK signalling pathway were significantly downregulated. Therefore, understanding the role of IAP and adenosine in inhibiting intestinal inflammation pathways may help inhibit intestinal inflammation by controlling the targeted genes, thereby preventing IR. The comparison of the transcriptome data with the qRT-PCR results showed that qRT-PCR and RNA-Seq revealed similar up- or downregulation patterns for these genes, thereby validating the RNA-Seq data (Figure S22).

Discussion

In this study, we developed an IAP + IAP enhancer with unique anti-inflammatory properties and demonstrated its therapeutic efficacy after oral administration in a murine IR model. However, most recent reports have focused on the use of oral IAP to treat intestinal inflammation-induced diseases such as metabolic syndrome (58) and hypertension (12). Oral IAP can be easily destroyed by acid pH (17). pH is increased by hydrotalcite as an intestinal alkalisation agent, and IAP activity improves; it has a certain remission effect on inflammation in vivo (15). Sung et al. (59) also found that CaCO3-based materials have potential for biomedical applications because of their safety and beneficial characteristics, such as pH sensitivity, CO2 gas generation, and antacid properties. Herein, to additionally incorporate antioxidant and anti-inflammatory functions, we speculated that the IAP enhancer can indirectly alleviate IR, and the deeper mechanism needs further study and discussion. We demonstrated that the extrusion–expansion mixture of food materials could increase the “milder” properties and achieve a slow-release effect similar to that of hydrotalcite. We also showed that the IAP enhancer could still reach the duodenum after it was exposed to gastric acid. IAP dephosphorylates LPS (60), ATP (11), and UDP (61). However, the effect of IAP on dephosphorylation has not been reported in the pH range (pH 5–8) in the small intestine of humans and other nucleoside
triphosphates. In this study, IAP effectively dephosphorylated LPS and nucleoside triphosphate in alkaline pH; thus, IAP + IAP enhancer could be effectively used in vitro. Therefore, these results showed the efficacy and safety of IAP + IAP enhancer and demonstrated that the combination of IAP and IAP enhancer plays critical and complementary roles in providing multifaceted benefits of IAP dephosphorylation.

HFD is associated with an imbalance in the normal composition and number of microbes in the gut. Among them, gram-negative bacteria can produce intestinal LPS, and gram-positive bacteria can produce a large number of luminal ATP and other nucleotide triphosphates (62). Although we based our study on a previous work that highlighted the preventive role of oral IAP against HFD-induced IR, few studies have investigated the prevalence of the IAP enhancer in IR. Although oat and xylitol improved IR in previous studies, the low dose used in our study was insufficient to produce a significant effect in 4 weeks (63, 64). Nevertheless, our data indicated that IAP + IAP enhancer could be an effective oral supplement against intestinal inflammation, thus protecting the host from IR. IAP in the lumen moves from the proximal small intestine to the distal large intestine; then, it becomes excreted in the faeces (65). Therefore, the faecal IAP level can directly reflect the IAP level as an indicator of early diagnosis of IR and is defined as "real-time IAP analysis" (22). The results showed that all HFD groups had less faecal IAP activity than the LFD control groups; however, IAP activity significantly increased after the treatment, especially IAP + IAP enhancer. Thus, IAP deficiency was associated with IR. This result also verified that oral IAP supplements could be a prevention/intervention for IR. However, because of the high IAP level in the small intestine, oral IAP supplementation is insufficient to significantly increase
the IAP level in the lumen. Therefore, other intervention approaches should include the upregulation of IAP in alkaline environments, which more likely increase IAP activities since such activities are higher in alkaline environments higher in alkaline environments than in acidic environments. The combined use of IAP + IAP enhancer showed that IAP not only supplemented but also promoted the in situ activation of IAP in the small intestine by increasing intestinal pH.

HFD administration led to an imbalance between pro-inflammatory and anti-inflammatory factors, and the anti-inflammatory effects of IAP + IAP enhancer were identified in this study. Previous studies demonstrated that IL-17 and IFN-γ negatively affect the gut barrier function (30). IL-22 is reduced in the intestine of obese mice, and restoration of IL-22 decreases metabolic abnormality by targeting intestinal permeability and endotoxemia (66). Improvement in gut barrier function and increased IL-22 levels are associated with the increase in the gene expression of tight junctions, including claudin 1 and ZO-1 (67). Our data showed that IAP + IAP enhancer modulated the gut barrier function partly by controlling the levels of these cytokines and thus prevented intestinal inflammation. Tight-junction proteins, such as ZO-1, occludin, and claudin-1, are important factors regulating intestinal permeability and major barrier components. When pathogenic bacteria and viruses attack, they hijack TJ proteins to enter and infect cells and promote inflammatory factor production (68). Our results showed that HFD downregulated the gene expression of ZO-1, occludin, and claudin-1, resulting in gut structure deterioration. IAP + IAP enhancer showed significantly increased claudin-1, occludin, and ZO-1 caused by HFD administration. This effect was consistent with that observed by Sulaiman (69), who found that the loss of IAP expression is associated with the decreased expression of intestinal junctional proteins and impaired barrier function. We showed that intestinal permeability was controlled by IAP + IAP enhancer, which was inversely associated with ZO-1, occludin, and claudin-1 expression levels. These results further confirmed the conclusion that IAP + IAP enhancer might regulate intestinal inflammation by maintaining the barrier function in vivo.

Two mechanisms could explain how IAP treatment alleviated intestinal inflammation in vitro (Figure 13), which led to IR. We mimicked LPS-induced intestinal inflammation that could demonstrate the IAP-mediated decrease in the LPS-induced cytokine production of TNF-α and IL-6. Interestingly, this study showed high levels of TNF-α/IL-6 production in unstimulated HT29 cells + leucocyte cocultures because neutrophils participate in the occurrence and maintenance of inflammation and release many inflammatory mediators. Activated neutrophils also release a large number of inflammatory mediators, such as cytokines, chemokines, and arachidonic acids, to promote inflammatory responses (70). The upregulated expression of NO derived from epithelial cells is related to the aggravation of IBD through iNOS (71). Moreover, the PGE₂ level in inflammatory tissues increases compared with that in intact mucous membranes in the pathogenesis of inflammatory bowel disease (72). Furthermore, LPS could produce NO and PGE₂, which were reduced after IAP treatment.

Under pathophysiological conditions, induced by inflammation or hypoxia, extracellular ATP release is enhanced, thereby accelerating inflammation and tissue injury (11). Adenosine produced via ATP hydrolysis has an anti-inflammatory property. Maria G Z et al. (73) found that guanosine is associated with its modulation of NF-kB nuclear translocation in DNBS-colitis rats. However, in this study, GTP

![Proposed intestinal inflammation protective mechanism of IAP.](https://example.com/gao.png)
Consequently, phosphatidylinositol 3 kinase (PI3K) activity increased, and the phosphorylation and increasing the Src kinase activity; upon binding to CXCR3 and CXCR3, resulting in Src responses. CXCL9 was downregulated in the IAP + LPS group. PI3K comprises a P110 catalytic subunit and a P85 regulatory subunit, which can be activated when P85 is activated (76); then, PI3K activates the P85 subunit of PI3K and its downstream effector factor Akt, thus triggering the PI3K-Akt signalling pathway (52). The interaction between SHC3 and GRB2-associated binding protein 1 (Gab1) activates the P85 subunit of PI3K and its downstream effector factor Akt, thus triggering the PI3K-Akt signalling pathway (52). 

The JAK-STAT signalling pathway is an immune-mediated inflammatory response triggered by dozens of cytokines (78). After the treatment of IAP + LPS and adenosine, the expression of IFN-stimulating genes (ISGs) was promoted by the JAK-STAT signalling pathway, and the IFNL1, IFNL2, and IFNL3 levels were significantly downregulated. The adenosine group also inhibited the non-receptor tyrosine kinase JAK family by inhibiting the dimerisation of THPO to MPL (54). CSF3 and CCL2 were downregulated in two groups. TRAF6 is inhibited by adenosine, while self-ubiquitinated TRAF6 binds to the TAK1 complex and activates the IKK complex; as a result, the NF-κB signalling pathway is activated (55). Numerous related proteins of NLRs are closely related to intestinal inflammation (79). In the IAP + LPS group, the NOD-like signalling pathway was inhibited by reducing HCK. However, the NOD2 content decreased after the adenosine treatment. HCK activates NLRP3 inflammasome by interacting with NLRP3 and promoting ASC oligomerisation (46); conversely, NOD2 consists of two N-terminal caspase activation and recruitment domains (CARDs), which initiate NF-κB by interacting with the serine and threonine kinase Rip2 (46). After IAP + LPS treatment, the expression of NF-κB signalling proteins and nuclear transcription factors, such as MEFV and SI00A8, was downregulated in HT-29 cells. The MAPK signalling pathway mediates intracellular signalling related to various cellular activities by adenosine treatment (80). NF-κB and MAPK signalling pathways do not function alone (cross talk). For example, inhibitors of ERK1/2 and P38 signalling pathways can inhibit NF-κB activity and P65 nuclear transfer (81). NF-κB and MAPKS signalling pathways are the most common inflammatory signalling pathways. 

Therefore, in this study, we found a new IR target, namely, IAP, which can dephosphorylate LPS and triphosphate nucleotide by supplementing and activating IAP in the intestinal tract; consequently, intestinal inflammation was controlled, and IR induced by intestinal inflammation was alleviated rather than control the gut microbes to alleviate IR and T2DM as other studies have reported. 

In conclusion, IR mice exhibited signs of intestinal inflammation that were linked to unfavourable changes in IR, urine pH, faecal IAP, inflammatory markers, LPS in serum, and gut barrier function. This study revealed that oral IAP and IAP enhancer could interfere with IR by controlling intestinal inflammation. IAP effectively inhibited the inflammation caused by LPS, while adenosine, the dephosphorylation product of IAP, had anti-inflammatory effects. Thus, this study provided an important basis for the development and utilisation of IAP and for the further processing and application of food and pharmaceutical industry resources.

**Data availability statement**

The datasets presented in this study can be found in online repositories. The name of the repository and accession number can be found below: NCBI Sequence Read Archive; accession PRJNA833108.

**Ethics statement**

The studies involving human participants were reviewed and approved by Changchun Jiahe Surgical Hospital. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and
approved by Northeast Agricultural University Committee on Animal Resources.

**Author contributions**

CG performed all cell studies and part of the animal experiment. MK performed the language checking and editing of the manuscript. WH performed analysed the animal experiment data. JL performed some physicochemical experiments. ND supervised the research. MH and MD analysed the data and wrote the manuscript. All authors read, revised (if needed), and approved the manuscript.

**Funding**

Funding from this article was from Talent Introduction Program of Northeast Agricultural University, Study on the production and mechanism of anti-inflammatory food B-HA/AP products.

**Acknowledgments**

We are grateful to the family described in this manuscript for their willingness to participate and interest in this research. We thank Dr. Pei for reading and editing the manuscript. We acknowledge Pro Han and members of the Food college laboratory for help with physicochemical experiments. We thank Shaoxing Huihui Biotechnology Co. for help with cell experiments. We thank the Laboratory of Molecular Nutrition and Immunity for valuable comments and discussion.

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Supplementary material**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.927272/full#supplementary-material
18. Koyama I, Matsunaga T, Harada T, Hoshii Y, Komoda T. Alkaline phosphatases reduce toxicity of lipopolysaccharides in vivo and in vitro through dephosphorylation. Clin Biochem (2002) 35(6):655–61. doi:10.1016/s0009-229x(02)00330-2

19. Liu Y, Cavallaro PM, Kim B-H, Liu T, Wang H, Kuehn F, et al. A role for intestinal alkaline phosphatase in preventing liver fibrosis. Theranostics (2021) 11(13):24–66. doi:10.7150/thno.34846

20. Kailanani K, Hamarneh SR, Economopoulos KP, Alam SN, Moaven O, Patel P, et al. Intestinal alkaline phosphatase prevents metabolic syndrome in mice. Proc Natl Acad Sci USA (2013) 110(17):7003–8. doi:10.1073/pnas.1218081110

21. Lassenius M, Fogarty CL, Blaut M, Haimala K, Rattinen L, Fjutu A, et al. Intestinal alkaline phosphatase at the crossroad of intestinal health and disease - a putative role in type 1 diabetes. J Internal Med (2017) 281(6):586–600. doi:10.1111/jim.12607

22. Malo MS. A high level of intestinal alkaline phosphatase is protective against type 2 diabetes mellitus irrespective of obesity. Endocrinology (2015) 12(2):2016–15. doi:10.1210/endo.2015.11.027

23. Oh-oka K, Kono H, Ishimaru K, Miyake K, Kubota T, Ogawa H, et al. Expressions of tight junction proteins occludin and claudin-1 are under the circadian control in the mouse Large intestine: Implications in intestinal permeability and susceptibility to colitis. PloS One (2014) 9(5):e98016. doi:10.1371/journal.pone.0098016

24. Hao W, Zha X, Liu Z, Song Y, Wu S, Lu X, et al. Resveratrol alleviates alternatively activated intestinal barrier dysfunction in mice. Environ Toxicol (2022) 37(3):1733–81. doi:10.1002/tox.23490

25. Lv H, Ren W, Zheng Y, Wang L, Gu Y, Pi et al. Tenunigen exhibits anti-inflammatory activity via inhibiting MAPK and NF-kappa b and inducing Nrf2-HO-1 signaling in macrophages. Food Funct (2016) 7(1):355–63. doi: 10.1039/c5fo00807g

26. Li J, Wang Y, Zhang C-G, Xiao H-J, Hu J-M, He J-D. Effect of long non-coding RNA GasR on proliferation, migration, invasion and apoptosis of colorectal cancer HT-29 cell line (vol 18, 4, 2018). Cancer Cell Int (2018) 18:14. doi:10.1186/s12935-018-0251-0

27. Yu Y, Yu X, Ma I, Tong Y, Yao J. Effects of NVP-BEZ235 on the circadian control in the mouse Large intestine: Implications in intestinal inflammation-London. Cell Physiol Biochem (2020) 8(1):600. doi:10.1186/s00928-021-1055-2

28. Lang S, Yang J, Yang K, Gu L, Cui X, Wei T, et al. Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal I-cell proliferation and GLP-1 production in type 2 diabetes. BMJ Open Diabetes Res Care (2020) 8(1):e010025. doi:10.1136/bmddrc-2019-010025

29. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol (2014) 14(5):329–42. doi:10.1038/nri3661

30. Cui J. Intestinal barriers against disease. Science (2018) 359(6380):1097–10. doi:10.1126/science.aat8035

31. He C, Yu T, Shi Y, Ma C, Yang W, Fang L, et al. MicroRNA 301A promotes intestinal inflammation and colitis-associated cancer development by inhibiting BTG1. Gastroenterology (2017) 152(3):1434. doi:10.1053/j.gastro.2017.01.049

32. Vicente-Sananes M, Horwitz AR. Cell migration: an overview. J Cell Physiol (2017) 232(6):1070–1077. doi:10.1002/jcp.25791

33. Peters E, Geraci S, Heimeskær S, Wilmer MJ, Bibos A, Kraenzlin B, et al. NOD2 protects the gut from experimental colitis spreading to small intestinal in vivo. Scandinavian J Immunol (2020) 91(1):e12840. doi: 10.1111/scij.12840

34. Kong X, Liao Y, Zhai L, Yang J, Cheng J, Yuan Z, et al. Hematopoietic cell kinase (HCK) is essential for NLRP3 inflammasome activation and lipopolysaccharide-induced inflammatory response In vivo. Front Immunol (2020) 11:580111. doi:10.3389/fimmu.2020.580111

35. Sharma D, Malik A, Balakrishnan A, Malreddi RS, Kanneganti TD. RIPK3 promotes m6f expression and pyrin inflammasome activation via modulation of mTOR signaling. J Immunol (2020) 205(10):2778–85. doi:10.4049/jimmunol.2000244

36. Gu A, Kim DH, Lee NR, Kim IS, Lee S. Chemotactic effect of s100a8 and s100a9 on human eosinophilic leukemia cells, EoL-1 through TLR4. Mol Cell Toxicol (2018) 14(1):329–36. doi:10.1515/mctox-2017-0063-y

37. Imai T, Hoshina K, Haskell C, Baba M, Nagura M, Nishimura M, et al. Identification and molecular characterization of fraktline receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell (1997) 91(4):521–30. doi:10.1002/(sici)1097-0046(19970206)91:4<309::aid-jic19>3.0.co;2-0

38. Pease JE, Williams TJ. Tipping the balance: A biased nanobody antagonist of ccr3 with potential for the treatment of eosinophilic inflammation. J Allergy Immunol (2019) 143(2):552–3. doi:10.1016/j.jaci.2018.10.052

39. Al Nabhani Z, Berrebi D, Martinez-Vinson C, Montcuquet N, Madre C, Roy M, et al. Nod2 protects the gut from experimental colitis spreading to small intestine. J Crohns Colitis (2020) 14(5):669–79. doi:10.1093/jcc/jjaa196

40. Cong J, Zhang L, Zhang Q, Li X, Xia XJ, Liu YF, et al. Lentinular vector-mediated SH3C silencing exacerbates oxidative stress injury in nigral dopamine neurons by regulating the PI3K-AKT-FoxO signaling pathway in rats with parkinson's disease. Cell Physiol Biochem (2018) 49(3):971–84. doi:10.1159/000495228

41. Son DS, Kabir SM, Dong YL, Lee E, Adnayeh SE. Characteristics of chemokine signatures elicited by EGF and TNF in ovarian cancer cells. J Immunol (2020) 205(2):1049–57. doi:10.4049/jimmunol.2004952

42. Dasouki M, Saadi I, Ahmed SO. THPO-MPL pathway and bone marrow failure. Hematol/Onkol Stem Cell Ther (2015) 8(1):6–9. doi:10.1007/s14055-014-0015-5

43. Teddy MJ, Wong GC, Liu XKK, Yamamoto H, Kasayama S, Kirkwood KL, et al. Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. J Biol Chem (2004) 279(4):2595–67. doi:10.1074/jbc.M308890200

44. Makondi PT, Chu CM, Wei PL, Chang YJ. Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer. PloS One (2017) 12(7):e010156. doi:10.1371/journal.pone.010156

45. Jiang J, Zhang ZW, Yu YC, Luan MC, Ma ZJ, Gao F, et al. Screening of Nogo/A-NTR-related differential genes in rat sciatic nerve injury signal pathway. Personalized Med (2019) 16(2):93–105. doi:10.2217/pme-2018-0088

46. Kuehn F, Duan R, Ilmer M, Adiliaghdam F, Schiergens TS, et al. Targeting the intestinal barrier to prevent gut-derived inflammation and disease: A role for intestinal alkaline phosphatase. Visceral Med (2021) 37(5):383–93. doi:10.1007/s12605-019-00510-9

47. Jung SY, Hwang H, Jo HS, Choi S, Kim HJ, Kim SE, et al. Tansylated calcium carbonate materials with antacid, anti-inflammatory, and antioxidant effects. Int J Mol Sci (2021) 22(9):4614. doi:10.3390/ijms22094614
60. Singh SB, Lin HC. Role of intestinal alkaline phosphatase in innate immunity. Biomolecules (2021) 11(12):1794. doi: 10.3390/biom11121794

61. Moss AK, Harmaneh SR, Mohamed MMR, Ramasamy S, Yammine H, Patel P, et al. Intestinal alkaline phosphatase inhibits the proinflammatory nucleotide uridine diphosphate. *Am J Physiology-Gastrointestinal Liver Physiol* (2013) 304(6): G597–604. doi: 10.1152/ajpgi.00435.2012

62. Lalles J-P. Luminal ATP: the missing link between intestinal alkaline phosphatase, the gut microbiota, and inflammation? *Am J Physiology-Gastrointestinal Liver Physiol* (2014) 306(10):G824–5. doi: 10.1152/ajpgi.00435.2013

63. Zhu Y, Dong LE, Huang L, Shi ZX, Dong JI, Yao Y, et al. Effects of oat beta-glucan, oat resistant starch, and the whole oat flour on insulin resistance, inflammation, and gut microbiota in high-fat-diet-induced type 2 diabetic rats. *J Funct Foods* (2020) 69:103939. doi: 10.1016/j.jff.2020.103939

64. Kishore P, Kehlenbrink S, Hu M, Zhang K, Gutierrez-Juarez R, Koppska S, et al. Xylitol prevents NEFA-induced insulin resistance in rats. *Diabetologia* (2012) 55(6):1808–12. doi: 10.1007/s00125-012-2527-z

65. Malo MS, Alam SN, Mostafa G, Zeller SJ, Johnson PV, Mohammad N, et al. Intestinal alkaline phosphatase inhibits the proinflammation, and gut microbiota in high-fat-diet-induced type 2 diabetic rats. *Nature* (2014) 514(7521):237. doi: 10.1038/nature13564

66. Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eisenschenk C, et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. *Nature* (2014) 514(7521):237. doi: 10.1038/nature13564

67. Lin M-E, Herr DR, Chun J. Lysosphosphatidic acid (LPA) receptors: Signaling properties and disease relevance. *Prostaglandins Other Lipid Mediators* (2010) 91(3-4):130–8. doi: 10.1016/j.prostaglandins.2009.02.002

68. Dell’Albani P, Santangelo R, Torrisi L, Nicoletti VG, de Vellis J, Giuffrida Stella AM. JAK/STAT signaling pathway mediates cytokine-induced iNOS expression in primary astroglial cell cultures. *J Neurosci Res* (2001) 65(5):417–24. doi: 10.1002/jnr.1

69. Rubino SJ, Selvanantham T, Girardin SE, Philpott DJ. Nod-like receptors in the control of intestinal inflammation. *Curr Opin Immunol* (2012) 24(4):398–404. doi: 10.1016/j.coi.2012.04.010

70. Zizzo MG, Caldarà G, Bellanca A, Nuzzo D, Di Carlo M, Serio R. Preventive effects of guanosine on intestinal inflammation in 2, 4-diaminobenzene sulfonic acid (DNBS)-induced colitis in rats. *Inflammopharmacology* (2019) 27(2):349–59. doi: 10.1007/s10787-018-0506-9

71. Poon RT, Shorthouse M, Hunter JO. Increased nitric oxide synthesis in ulcerative colitis. *Lancet* (1993) 341(8843):465–6. doi: 10.1016/0140-6736(93)90211-x

72. Krause W, DuBois RN. Eicosanoids and the large intestine. *Prostaglandins Other Lipid Mediators* (2000) 61(3–4):145–61. doi: 10.1016/s0090-6980(00)00069-1

73. Page J, Yilmaz MS, Kuscu C, Suer O, Yalcin M, Mutu D, Savci V. Hypotensive effects of intravenously administered uridine and cytidine in conscious rats. *Involvement of adenosine receptors. Eur J Pharmacol* (2008) 584(1):125–36. doi: 10.1016/j.ejphar.2008.01.044

74. Jackson NE, Gillepie DG. Regulation of cell proliferation by the guanosine-adenosine mechanism: Role of adenosine receptors. *Physiol Rev* (2013) 12(3):e8024–4. doi: 10.1002/phy2.24

75. van der Jager, S., van Engelen, M. L., van der Velden, W., Berendsen, H., de Vos, B., Roufogalis, B. D., et al. PPAR-alpha activation as a preconditioning-like intervention in rats. *Am J Physiology-Gastrointestinal Liver Physiol* (2018) 102(4):542. doi: 10.1097/PHY.0000000000002062

76. Kulkarni U, Goldstein DR. Converging roles for neutrophils: Promoting and resolving inflammation? *Transplantation* (2018) 102(4):542. doi: 10.1097/tp.0000000000002062

77. Middelton SJ, Shorthouse M, Hunter JO. Increased nitric oxide synthesis in ulcerative colitis. *Lancet* (1993) 341(8843):465–6. doi: 10.1016/0140-6736(93)90211-x

78. Lin M-E, Herr DR, Chun J. Lysosphosphatidic acid (LPA) receptors: Signaling properties and disease relevance. *Prostaglandins Other Lipid Mediators* (2010) 91(3-4):130–8. doi: 10.1016/j.prostaglandins.2009.02.002

79. Dell’Albani P, Santangelo R, Torrisi L, Nicoletti VG, de Vellis J, Giuffrida Stella AM. JAK/STAT signaling pathway mediates cytokine-induced iNOS expression in primary astroglial cell cultures. *J Neurosci Res* (2001) 65(5):417–24. doi: 10.1002/jnr.1

80. Rubinso SJ, Selvanantham T, Girardin SE, Philpott DJ. Nod-like receptors in the control of intestinal inflammation. *Curr Opin Immunol* (2012) 24(4):398–404. doi: 10.1016/j.coi.2012.04.010

81. Parthasarathy G, Philipp MT. The MEK/ERK pathway is the primary conduit for borrelia burgdorferi-induced inflammation and P33-mediated apoptosis in oligodendrocytes. *Apoptosis* (2014) 19(1):76–89. doi: 10.1007/s10495-013-0913-8